Two Sigma Securities’s Dermata Therapeutics DRMA Stock Holding History

Two Sigma Securities’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,472	Closed	-$8.61K	–	1536
2025 Q2	$8.61K	Buy	+1,472	New	+$11.3K	﹤0.01%	1312
2024 Q2	–	Sell	-133	Closed	-$8.2K	–	3127
2024 Q1	$8.2K	Buy	+133	New	+$9.15K	﹤0.01%	2786
2023 Q4	–	Sell	-74	Closed	-$11.8K	–	3148
2023 Q3	$11.8K	Buy	+74	New	+$14.2K	﹤0.01%	2669
2023 Q1	–	Sell	-5	Closed	-$5.09K	–	2800
2022 Q4	$5.09K	Buy	+5	New	+$6.27K	﹤0.01%	2449

Other funds holding DRMA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's DRMA Position: Q3 2025 in Review

Two Sigma Securities sold out of Dermata Therapeutics (DRMA) in Q3 2025, closing a stake of 1,472 shares — an estimated $8.61K sold.

Two Sigma Securities first reported a position in DRMA in Q4 2022 and held it in 4 quarters. The position peaked at $11.8K in Q3 2023. 5 funds tracked by Wall St. Rank hold DRMA as of Q3 2025.

Two Sigma Securities reported no remaining Dermata Therapeutics position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 1,472 Dermata Therapeutics shares in Q3 2025, an estimated $8.61K.
Two Sigma Securities first reported a position in Dermata Therapeutics in Q4 2022 and held it in 4 quarters.
Two Sigma Securities's Dermata Therapeutics position peaked at $11.8K in Q3 2023.
5 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.